Relmada Therapeutics (RLMD) Enterprise Value Growth (3y) (2017 - 2026)

Relmada Therapeutics (RLMD) Enterprise Value Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Relmada Therapeutics 205.29 Mn 205.29 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.89%
Dec 31, 2025 14.41%
Sep 30, 2025 57.75%
Jun 30, 2025 54.01%
Mar 31, 2025 50.32%
Dec 31, 2024 40.38%
Sep 30, 2024 14.99%
Jun 30, 2024 13.56%
Mar 31, 2024 6.63%
Dec 31, 2023 6.30%
Sep 30, 2023 4.79%
Jun 30, 2023 4.03%
Mar 31, 2023 -4.84%
Dec 31, 2022 -8.40%
Sep 30, 2022 -186.27%
Jun 30, 2022 -184.38%
Mar 31, 2022 -375.38%
Dec 31, 2021 -343.65%
Sep 30, 2021 -363.00%
Jun 30, 2021 -265.22%